SLC5A2 and heart failure: Studies such as EMPA-REG OUTCOME, CANVAS, and DECLARE-TIMI58 have shown the cardiovascular safety of SGLT2 inhibitors in diabetic patients (Zinman et al., 2015b; Neal et al., 2017b; Wiviott et al., 2019b), particularly in reducing the risk of heart failure hospitalization.